Author Archives: Robert Fuller

HealthStream ICD-10 Delay Should Be a Modest Positive

HealthStream ICD-10 Delay Should Be a Modest Positive

Last week, legislation delayed the transition to the ICD-10 coding system for one year, to October 1, 2015. HealthStream has captured meaningful market share for ICD-10 training, and revenue from ICD-10 content was 13% of sales in fourth quarter 2013, leaving some investors concerned that it is a temporary driver that has been inflating revenue

Alliance Data Systems Corporation March Data Suggests Solid March-Quarter

Alliance Data Systems (ADS) reported monthly data for March; charge-offs and loan growth were modestly better than our expectations, and delinquencies were consistent with historical seasonal trends. In March, net charge-offs for the managed portfolio rose 10 basis points month-to-month, to 4.7%, and 30-day-plus delinquencies fell 40 basis points month-to-month, to 3.9%. For the March

Luxottica Signs New License Agreement With Michael Kors

Luxottica and Michael Kors announced a new exclusive 10-year license agreement under which Luxottica will design, manufacture, and distribute prescription frames and sunglasses for Michael Kors beginning spring 2015. Michael Kors had previously worked with smaller eyewear manufacturer Marchon since 2004. The agreement is positive for both Luxottica and Michael Kors. With regard to Luxottica,

ICON Acquisition of Aptiv Solutions Consistent With Strategy

Monday, March 31, ICON announced its intention to acquire Aptiv Solutions, a provider of global outsourced development services, for roughly $145 million. The company focuses on technology to enable adaptive clinical trials—a nice complement to ICON’s existing software offering through Firecrest and ICONIK. In addition, Aptiv owns an oncology focused full service CRO in Japan.

Immunomedics Up 5% After Announcing Its New Studies About Development Of Cancer Products

Immunomedics Up 5% After Announcing Its New Studies About Development Of Cancer Products.

TetraLogic Pharmaceuticals Buying Shape Pharmaceuticals for Upfront Payment of $13 Mln Plus Future Royalties – Halted in Evening Action

TetraLogic Pharmaceuticals Buying Shape Pharmaceuticals for Upfront Payment of $13 Mln Plus Future Royalties – Halted in Evening Action

Top